ArticleJAMA network open2024
Seizure Duration and Electroconvulsive Therapy in Major Depressive Disorder.
Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Ictal electroencephalography and heart rate as treatment criteria in electroconvulsive therapy: a systematic review of the literature.European archives of psychiatry and clinical neuroscience · 2026Pooled it
- Comparative efficacy and cognitive safety of magnetic seizure therapy and electroconvulsive therapy in major depressive disorder: a systematic review and meta-analysis.Frontiers in psychiatry · 2026Pooled it
- Propofol Versus Methohexital in Electroconvulsive Therapy: Impact on Treatment Efficacy and Adverse Effects. A Systematic Literature Review and Meta-Analysis.Acta anaesthesiologica Scandinavica · 2025Pooled it
- Article
- Clinical Outcomes and Treatment Characteristics of Seizure Threshold-Titrated Electroconvulsive Therapy in Depressive Disorder: A 3.5-Year Retrospective Naturalistic Course-Level Study.Journal of clinical medicine · 2026Article
- Microbiome-Informed Precision Electroconvulsive Therapy: Oral-Gut-Immune Signatures and Seizure Biology as Candidate Predictors of Response-A Narrative Review.Biomedicines · 2026Review
- Brain morphometry, stimulation charge, and seizure duration in electroconvulsive therapy.Molecular psychiatry · 2026Article
- Association between serum concentrations of psychotropic drugs and seizure quality during ECT treatment.BMC psychiatry · 2026Article
- Identifying Immunological Biomarkers for Major Depressive Disorder: Insights From Machine Learning, Single-Nucleus Bioinformatics, and Experimental Validation.BioMed research international · 2026Article
- Depth of Anaesthesia Measured by Patient State Index (PSi) Does Not Correlate With Increased Seizure Duration During Electroconvulsive Therapy.Acta anaesthesiologica Scandinavica · 2026Observational
- Electroconvulsive therapy-induced motor seizure length trajectories and their association with clinical remission: a retrospective cohort study across diagnoses.Frontiers in psychiatry · 2026Article
- Electroconvulsive therapy generates a postictal wave of spreading depolarization in mice and humans.Nature communications · 2025Article
- Age and First Seizure Length in Electroconvulsive Therapy.JAMA network open · 2025Article
- Treat to Sedation: Managing Intravenous Placement for Electroconvulsive Therapy in Autism with Intellectual Disability and Hyperactive Catatonia.Journal of child and adolescent psychopharmacology · 2025Article
- Electroconvulsive Therapy: A Scotland-Wide Naturalistic Study of 4826 Treatment Episodes.Biological psychiatry global open science · 2025Article
- Machine learning based seizure classification and digital biosignal analysis of ECT seizures.Scientific reports · 2025Article
- Efficacy and safety of intravenously applied caffeine augmentation in electroconvulsive therapy.Neuroscience applied · 2025Article
- Electroconvulsive therapy for obsessive-compulsive disorder: clinical efficacy and predictive role of inflammatory markers.Frontiers in psychiatry · 2025Article
- Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Electroconvulsive therapy (ECT), wherein a generalized epileptic seizure is induced, is a treatment for major depressive disorder (MDD). Currently, it is unclear whether there is an association between seizure length and treatment outcome. Objective: To explore the association between seizure duration, potential confounding variables, and ECT treatment outcome. Design, Setting, and Participants: This population-based cohort study obtained data from the Swedish National Quality Register for ECT. Patients treated for unipolar MDD with unilateral electrode placement between January 1, 2012, and December 31, 2019, were included. The electroencephalographic (EEG) seizure duration from the first ECT treatment session for each patient was used for analysis. Data analyses were performed between March 2021 and May 2024. Main Outcomes and Measures: The primary outcome was remission, defined as a cutoff score of less than 10 points on the self-assessment version of the Montgomery-Åsberg Depression Rating Scale within 1 week after ECT. Multivariate logistic regression analysis was performed to calculate odds ratios (ORs) between different seizure duration groups. Furthermore, the associations between concomitant use of pharmacological treatments, seizure duration, and remission rate were explored. Results: Among the 6998 patients included, 4229 (60.4%) were female and the mean (SD) age was 55.2 (18.6) years. Overall, 2749 patients (39.3%) achieved remission after ECT. Patients with EEG seizure duration of 60 to 69 seconds had the highest remission rates compared with patients with seizure duration of less than 20 seconds (OR, 2.17; 95% CI, 1.63-2.88; P < .001). Anticonvulsant medications were associated with shorter seizure duration (eg, lamotrigine: β coefficient [SE], -6.02 [1.08]; P < .001) and lower remission rates (eg, lamotrigine: adjusted OR, 0.67; 95% CI, 0.53-0.84; P < .001). Conclusions and Relevance: This study found an association between seizure length and remission from MDD. Use of anticonvulsant medication during ECT was associated with shorter seizure duration and lower remission rates after ECT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.